PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment strategies.

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements.

Triple-positive breast cancer is a type of breast cancer that tests positive for estrogen receptors, progesterone receptors, and high levels of HER2 protein. Some types of breast cancer cells use ...

Maternal stress is a major risk factor for preterm birth (PTB), with recent mouse studies highlighting the role of FKBP51 in ...

Parturition is a complex and involved process. Within the protected confines of the mother, the fetus grows rapidly for 37–42 weeks until the right combination of signals, stemming from both ...